Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with locally advanced or inoperable liver cancer (hepatocellular carcinoma), confirmed through a tissue biopsy or sample.
- People whose general health and ability to carry out daily activities meets a specific standard, rated 0 or 1 on a medical scale (meaning fully active or able to carry out light activity).
- People who have not previously received any systemic (whole-body) treatment, such as chemotherapy or immunotherapy, for their advanced or inoperable liver cancer.
- People whose cancer can be measured using standard medical imaging criteria (confirm with trial site).
Who may not be able to join:
- People who have significant bleeding problems, blood clotting disorders, or other signs of serious bleeding risk.
- People who have had an organ transplant or who have an autoimmune disease (a condition where the immune system attacks the body's own tissues).
- There are additional criteria not listed here that the trial site will assess.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Australian sites
61295150056
+617520203155
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with adverse events (AEs); Number of participants with serious adverse events (SAEs) (as per Common Terminology Criteria for Adverse Events v5 (CTCAE v5)); Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria; Number of participants with AEs leading to discontinuation; Number of participants with AEs leading to death; Objective response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.